Global Aminoglycosides Market - 2023-2030

Market Overview

The global aminoglycosides market reached US$ 1,636.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,202.2 million by 2030. The global aminoglycosides market is expected to exhibit a CAGR of 3.8% during the forecast period (2023-2030).

The global aminoglycosides market is a thriving sector in the pharmaceutical industry, focusing on the treatment of severe bacterial infections. Aminoglycosides are significant antibiotics that are widely utilized in hospitals, clinics, and research laboratories. Recent market trends reveal an increase in demand for combination medicines as well as a noticeable emphasis on developing novel formulations. Significant developments in the global aminoglycosides market include R&D initiatives, regulatory approvals, and a rising application in veterinary medicine.

The growing prevalence of bacterial infections, the increasing aging population, and high antibiotic usage are the factors driving the global aminoglycoside market. The growing geriatric population is increasing the demand for aminoglycoside drugs. According to WHO 2022 projection, the global population aged 60 and up is expected to grow dramatically. By 2030, one in every six individuals worldwide will be 60 or older, with the population in this age group estimated to reach 1.4 billion, up from 1 billion in 2020.

Market Dynamics

The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.

The rising incidence of tuberculosis is one of the main factors driving the significant rise of the global aminoglycoside market. Strong antibiotics like aminoglycosides are necessary for the efficient treatment of tuberculosis, a serious bacterial illness. The need for aminoglycosides is growing as a result of the rising prevalence of tuberculosis, particularly in developing nations.

For instance, according to the Centers for Disease Control and Prevention report of 2023, in 2022, there were 8,300 reported cases of tuberculosis (TB) in the United States, resulting in a rate of 2.5 cases per 100,000 people. This is a modest rise from the 7,874 cases reported in 2021. In 2022, the incidence of tuberculosis remained at 2.5 incidents per 100,000 people.

The Growing Demand for Aminoglycoside in Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market.

The use of aminoglycosides in veterinary medicine has been continuously expanding, offering market players a lucrative opportunity. In livestock, companion animals, and aquaculture, aminoglycosides are commonly used to treat bacterial infections. These aminoglycosides are administered in-feed and in-water form in poultry and pig industries.

For instance, Mycoplasma and Escherichia coli are the most frequent causes of respiratory infections in poultry that need to be treated with aminoglycosides. Animals can be treated with aminoglycosides for bacterial infections Escherichia coli, Proteus, Pseudomonas, Salmonella, Shigella, Serratia, and Enterobacter. Owing to these reasons, veterinary medicine usage in bacterial infection will drive the global aminoglycosides market over the forecast period.

The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.

Antibiotic resistance is the ability of bacteria to tolerate the effects of antibiotics, rendering them useless in treating bacterial infections. Prolonged and inappropriate usage of aminoglycosides has contributed to the development of bacterial strains resistant to these antibiotics, decreasing their efficiency.

For instance, Methicillin-resistant Staphylococcus aureus (MRSA) and bacteria producing extended-spectrum beta-lactamase (ESBL) are becoming resistant to aminoglycosides. Infected patients' aminoglycoside resistance rates, phenotypes, and mechanisms have all been reported. Antibiotic-resistant bacteria, such as MRSA and ESBL-producing bacteria, are becoming a rising public health threat.

COVID-19 Impact Analysis

The COVID-19 outbreak has had a substantial influence on the global aminoglycosides industry. The pandemic disrupted worldwide supply chains and reduced demand for goods and services in a variety of industries, including the aminoglycosides industry. One of the most significant effects of COVID-19 on the aminoglycosides market is the disruption of supply chains, which has resulted in a decline in aminoglycoside antibiotic production.

The pandemic has also increased antibiotic usage, as individuals are becoming more concerned about their health and taking adequate prescriptions to avoid infections and lengthier hospital stays. However, aminoglycosides may have particular benefits in the fight against COVID-19. According to a 2021 paper published by the National Library of Medicine, aminoglycosides have the potential to be SARS-CoV-2 antivirals. In vitro, inhibition of murine hepatitis virus (MHV) was demonstrated by the aminoglycosides hygromycin B (hygB) and neomycin. Others discovered hygB activity against bovine and feline coronaviruses.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine is expected to have a substantial influence on the global aminoglycoside market. Because of the incidence of infectious diseases in war zones, has led to higher pricing, supply chain interruptions, and increased demand for aminoglycosides. These factors are predicted to reduce market demand, raise prices, and disrupt the supply chain, making it difficult for patients to get essential aminoglycoside drugs.

Furthermore, the conflict's indirect effects, such as lower economic growth and lower demand for healthcare services, may contribute to the market's pessimistic view. While the full extent of the conflict's impact is unknown, it is clear that the global aminoglycosides industry will be severely impacted.

Segment Analysis

The global aminoglycosides market is segmented based on product type, route of administration, application, and region.

The Gentamicin Segment is expected to hold a Dominant Position for the Global Aminoglycoside Market over the Forecast Period.

The gentamicin segment accounted for the highest market share accounting for approximately 27.3% of the aminoglycoside market in 2022. Gentamicin is an antibiotic that is commonly used to treat severe bacterial infections in many regions of the body. It is the preferred treatment for serious infections, and its market expansion is being supported by expanded R&D.

A recent study conducted in 2022 and entitled "Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review" highlights the efficiency of a typical starting dose of 7 mg/kg based on total body weight in both adults and children older than one month, including critically ill patients. The likelihood of attaining the targeted treatment outcome is observed to be higher with this dosing technique. Thus, owing to the above factors, the market segment is expected to hold the largest market share for the global aminoglycoside market over the forecast period.

Geographical Analysis

North America holds a Dominant Position in the Global Aminoglycoside Market.

North America is estimated to hold around 36.9% of the total market share throughout the forecast period. The high disposable income, presence of major market players, an aging population, high prevalence of bacterial infections, and rising incidence of antibiotic resistance are some of the key factors expected to drive the aminoglycoside market in North America region over the forecast period.

The market for antibiotic formulations containing aminoglycosides is expanding significantly as a result of the involvement of several manufacturers in their creation. A significant milestone was reached by the U.S.-based company Padagis in March 2022 when the FDA gave the generic version of Tobradex ophthalmic suspension, which has an AB rating, the go-ahead. Tobramycin and dexamethasone make up this medication's active components.

Tobradex Ophthalmic Suspension is primarily used for the treatment of inflammatory, steroid-responsive ocular disorders where a corticosteroid is necessary, as well as when there is a risk of superficial bacterial ocular infection. Hence, owing to the above factors, the market is expected to drive over the forecast period

Competitive Landscape

The major global players in the market include: Pfizer Inc, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals. Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, and Kremoint Pharma Pvt. Ltd., among others.

Why Purchase the Report?

• To visualize the global aminoglycosides market segmentation based on the product type, route of administration, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aminoglycosides market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global aminoglycoside market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies